Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H24N4O4 |
Molecular Weight | 384.429 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
InChI
InChIKey=IQVRBWUUXZMOPW-PKNBQFBNSA-N
InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
Molecular Formula | C20H24N4O4 |
Molecular Weight | 384.429 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Istradefylline is a first-in-class adenosine A2A receptor antagonist antiparkinsonian agent and has been marketed as the brand name NOURIAST® in Japan since May 30, 2013. NOURIAST is indicated for the improvement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment
with levodopa-containing products.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL251 |
12.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NOURIAST Approved UseImprovement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment
with levodopa-containing products. Launch Date2013 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
230.9 ng/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISTRADEFYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3249 ng × h/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISTRADEFYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72.1 h |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISTRADEFYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISTRADEFYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 65 years (range: 33 - 84 years) Health Status: unhealthy Age Group: 65 years (range: 33 - 84 years) Sex: M+F Sources: |
Disc. AE: Dyskinesia... AEs leading to discontinuation/dose reduction: Dyskinesia (6%) Sources: |
120 mg 1 times / day steady, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Chest pain... Other AEs: Chest pain (0.7%) Sources: |
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
120 mg single, oral Overdose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Hallucinations, Agitation... Other AEs: Hallucinations Sources: Agitation Dyskinesia |
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Visual hallucinations, Hallucination olfactory... Other AEs: Auditory hallucinations... AEs leading to discontinuation/dose reduction: Visual hallucinations (1%) Other AEs:Hallucination olfactory (1%) Somatic hallucination (1%) Auditory hallucinations (1%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dyskinesia | 6% Disc. AE |
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 65 years (range: 33 - 84 years) Health Status: unhealthy Age Group: 65 years (range: 33 - 84 years) Sex: M+F Sources: |
Chest pain | 0.7% | 120 mg 1 times / day steady, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Agitation | 120 mg single, oral Overdose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Dyskinesia | 120 mg single, oral Overdose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Hallucinations | 120 mg single, oral Overdose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Auditory hallucinations | 1% | 40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hallucination olfactory | 1% Disc. AE |
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Somatic hallucination | 1% Disc. AE |
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Visual hallucinations | 1% Disc. AE |
40 mg 1 times / day steady, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Sample Use Guides
In Vivo Use Guide
Sources: http://www.e-search.ne.jp/~jpr/PDF/KYOWA13.PDF
To be administered concomitantly with levodopa-containing products.
The usual adult dosage of istradefylline is 20 mg orally administered once daily. According to
symptoms, 40 mg of istradefylline can be orally administered once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23812646
The binding kinetics of istradefylline to the human A2A receptor
were investigated using 1 nmol/L of [3H]-istradefylline binding to the human A2A receptor.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:43:12 GMT 2025
by
admin
on
Wed Apr 02 09:43:12 GMT 2025
|
Record UNII |
2GZ0LIK7T4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C38149
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6559
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
NOURIAST
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | APPROVED MARCH 2013 | ||
|
5311037
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
2199015
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
8387
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
DB11757
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL431770
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
155270-99-8
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
2GZ0LIK7T4
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
DTXSID7057652
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
ISTRADEFYLLINE
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
2GZ0LIK7T4
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
C111599
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
C73268
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
100000152133
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
SUB126676
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
4882
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
OO-61
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY | |||
|
5608
Created by
admin on Wed Apr 02 09:43:12 GMT 2025 , Edited by admin on Wed Apr 02 09:43:12 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TARGET->WEAK INHIBITOR |
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
EXCRETED UNCHANGED |
AMOUNT ADMINISTERED
FECAL
|
||
|
TARGET->WEAK INHIBITOR |
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||